ODTX (Odyssey Therapeutics) DeferredTaxAndRevenue: $3.17 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ODTX Odyssey Therapeutics Inc ODTX
13 GF Score
Price $26.49
! 2 Warning Signs
View Full Analysis

What is Odyssey Therapeutics DeferredTaxAndRevenue?

Odyssey Therapeutics ODTX +6.93% 13 DeferredTaxAndRevenue is $3.17 Mil as of Jun. 2026. GuruFocus rates ODTX with a GF Score™ of 13/100. The stock has 2 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Odyssey Therapeutics's current deferred tax and revenue for the quarter that ended in Jun. 2026 was $3.17 Mil.

Odyssey Therapeutics DeferredTaxAndRevenue Related Terms

Odyssey Therapeutics DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Odyssey Therapeutics's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Odyssey Therapeutics DeferredTaxAndRevenue Chart

Odyssey Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
DeferredTaxAndRevenue
1.00 0.41 6.77 0.06

Odyssey Therapeutics Quarterly Data
Dec22 Dec23 Sep24 Dec24 Mar25 Jun25 Dec25 Mar26 Jun26
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.06 1.45 3.17
ODTX
13GF Score
Odyssey Therapeutics Inc ODTX
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of $3.17 Mil mean?
Odyssey Therapeutics (ODTX) has a DeferredTaxAndRevenue of $3.17 Mil as of Jun. 2026. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Odyssey Therapeutics.
Is Odyssey Therapeutics' DeferredTaxAndRevenue too high?
Odyssey Therapeutics' current DeferredTaxAndRevenue is $3.17 Mil. Overall, Odyssey Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Odyssey Therapeutics' DeferredTaxAndRevenue compare to SANA and GERN?
Odyssey Therapeutics' DeferredTaxAndRevenue of $3.17 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Biotechnology company?
A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Odyssey Therapeutics. Odyssey Therapeutics's current DeferredTaxAndRevenue is $3.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Odyssey Therapeutics stock overvalued right now?
Odyssey Therapeutics (ODTX) has a current DeferredTaxAndRevenue of $3.17 Mil. The current DeferredTaxAndRevenue is $3.17 Mil. Odyssey Therapeutics' overall GF Score™ is 13/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Odyssey Therapeutics (ODTX), the current DeferredTaxAndRevenue is $3.17 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Odyssey Therapeutics Business Description

Address 51 Sleeper Street, Boston, MA, USA, 02210
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.
13GF Score

Get the complete analysis for ODTX

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.49
Price